BMO Capital analyst Evan Seigerman initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Outperform rating and announces Price Target of $40.
Last summer, Federal Reserve chair Jerome Powell laid out a plan to reset the U.S. housing market, which has been putting the squeeze on aspiring homeowners.
How? By increasing interest rates, and subsequently spiking mortgage rates.